ZECCHIN, Davide

ZECCHIN, Davide  

ONCOLOGIA  

Mostra records
Risultati 1 - 11 di 11 (tempo di esecuzione: 0.038 secondi).
Titolo Data di pubblicazione Autore(i) File
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer. 2013 Bardelli A*;Corso S*;Bertotti A*;Hobor S;Valtorta E;Siravegna G;Sartore-Bianchi A;Scala E;Cassingena A;Zecchin D;Apicella M;Migliardi G;Galimi F;Lauricella C;Zanon C;Perera T;Veronese S;Corti G;Amatu A;Gambacorta M;Diaz LA Jr;Sausen M;Velculescu VE;Comoglio P;Trusolino L;Di Nicolantonio F;Giordano S;Siena S (*Co-First Authors)
BRAF V600E is a determinant of sensitivity to proteasome inhibitors. 2013 Zecchin D;Boscaro V;Medico E;Barault L;Martini M;Arena S;Cancelliere C;Bartolini A;Crowley EH;Bardelli A;Gallicchio M;Di Nicolantonio F
EVALUATION OF DRUG RESPONSES IN NON-TRANSFORMED CELLS CARRYING CANCER ALLELES 2009 Gallicchio M; Di Nicolantonio F; Arena S.; Zecchin D; Martini M; Flonta S; Stella G; Lamba S; Cancelliere C; Russo M; Geuna M; Appendino G; Fantozzi R; Medico E; Bardelli A.
Knock in of cancer mutations in human cells predicts pharmacologicalresponse to targeted therapies 2011 Valentina Boscaro; Davide Zecchin; Federica Di Nicolantonio; Alberto Bardelli; Margherita Gallicchio
Knock-in of oncogenic mutations in human somatic cells as a tool to identify genoselective compounds 2007 Federica Di Nicolantonio; Sabrina Arena; Margherita Gallicchio; Miriam Martini; Davide Zecchin; Simona Flonta; Giulia Stella; Giovanni Appendino; Roberto Fantozzi; Enzo Medico; Alberto Bardelli
Modeling tumor progression and identifying genotype-drug interactions by the sequential introduction of cancer mutations into the genome of human normal cells 2011 Davide Zecchin; Margherita Gallicchio; Valentina Boscaro; Francesco Sassi; Enzo Medico; Federica Di Nicolantonio; Alberto Bardelli.
Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells 2013 Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A.
Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. 2014 Sun C;Wang L;Huang S;Heynen GJ;Prahallad A;Robert C;Haanen J;Blank C;Wesseling J;Willems SM;Zecchin D;Hobor S;Bajpe PK;Lieftink C;Mateus C;Vagner S;Grernrum W;Hofland I;Schlicker A;Wessels LF;Beijersbergen RL;Bardelli A;Di Nicolantonio F;Eggermont AM;Bernards R
Tracking the genomic evolution of breast cancer metastasis 2010 Zecchin D; Bardelli A
Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR 2012 Prahallad A*; Sun C*; Huang S*; Di Nicolantonio F*; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R (*shared first authorship)
Unveiling of BRAF V600E Mutant Cells Sensitivity to Proteasome Inhibitors Using an Isogenic Cell Based Screening 2013 V. Boscaro; D. Zecchin; A. Bardelli; F. Di Nicolantonio; M. Gallicchio